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SUMMARY
Nutraceuticals are potentially healthful foods that play a role in maintaining human well
being, enhancing health and preventing, or even treating, specific diseases. More than for
any other diseases, cardiovascular diseases occur in association with risk factors that are
amenable to prevention or treatment by nutraceutical interventions. Several ingredients
marketed for use in dietary supplements address such risk factors. The ability of nutraceu-
ticals to favorably influence cardiovascular risk factors and atherosclerotic vascular disease
should be recognized as an enormous opportunity for the prevention or treatment of this
common condition. In this review, we attempt at summarizing some of the recent research
findings on ω-3-polyunsaturated fatty acids and antioxidant polyphenols that have bene-
ficial cardiovascular effects to update the practicing clinicians on the potential benefits of
nutraceuticals in this area.
“Let food be thy medicine and medicine be thy food”
Hyppocrates (460–377 B.C.)
Introduction
Cardiovascular diseases (CVD), of which atherosclerotic vascular
disease is by far the largest component, remain the leading cause of
morbidity and mortality worldwide. Although genetic factors and
aging are important in determining the overall risk, a substantial
proportion of CVD occur in conjunction with a series of modifiable
risk factors, such as hypercholesterolemia, hypertension, obesity,
insulin resistance, and diabetes, susceptible to lifestyle modifica-
tions, which include diet and physical exercise [1]. Such aware-
ness has spurred, in the last 50 years, a growing worldwide in-
terest on the prospect that more appropriate eating habits can
promote and maintain a healthy life. In the past, health-focused
dietary approaches have mostly focused on the curtailment of di-
etary sodium, refined sugars, and saturated fats. In more recent
years, however, attention of researchers and of the media has ex-
panded on trying to promote the consumption of “curative nutri-
ents.” This approach has gained large support because people in
general appear to prefer consuming increased amounts of specific
foods rather than restricting themselves from something they like.
Such a renewed hyppocratic perception of “food as a medicament”
has encouraged pharmaceutical and biotechnology companies to-
ward the search and the marketing of a growing number of new
substances, from dietary supplements to nutraceuticals (Table 1),
with the aim of improving human health, making us fitter and
more resilient to disease. Because the scientific characterization
and commercial regulation of such substances vary from country
to country [2,3], their popularity imposes the medical and scien-
tific community a constant revision of their therapeutic potentials.
On this background, this short review will focus on summariz-
ing the main mechanistic evidence supporting the consumption of
selected nutraceuticals and functional foods generically labeled as
“cardioprotective” to prevent CVD.
The Pathogenesis of Atherosclerotic
Vascular Disease—Focus on the
Orchestrating Role of the Vascular
Endothelium
Because a description of the cellular and molecular events un-
derlying atherosclerosis is important for the understanding of the
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Table 1 Definitions of dietary supplements, nutraceuticals, and functional foods
Dietary supplements
(United States Government Office,
1994)
A product (other than tobacco) in the form of a capsule, powder, softgel, or gelcap intended to supplement the diet
to enhance health that bears or contains one or more of the following dietary ingredients: a vitamin, mineral, amino
acid, or other botanical or dietary substance.
Phytochemical
(Bloch and Thomson, 1995)
Substances found in edible fruit and vegetables that can be ingested daily (in quantities of grams) by humans and
that exhibit a potential to favorably modulate humanmetabolism to prevent cancer and other diseases (isoflavones,
resveratrol, garlic allyl-sulphides, tomato lycopene, onion quercetin, etc.).
Nutraceuticals
(De Felice, 1995)
Food or part of food that providesmedical or health benefits, including the prevention and/or treatment of a disease.
Nutraceuticals
(Zeisel, 1999)
A diet supplement that delivers a concentrated form of a biologically active component of food in a nonfood matrix
to enhance health.
Functional food
(Zeisel, 1999)
Nutrient consumed as part of a normal diet but delivering one or more active ingredients (that have physiologic
effects and may enhance health) within the food matrix.
Functional food
(Hardy, 2000)
Any food or ingredient that has a positive impact on an individual’s health, physical performance, or state of mind,
in addition to its nutritive value.
mode of action of cardiovascular nutraceuticals, a short review
of current concepts of inflammation and atherosclerosis gives the
proper background to place their effects in context.
In its initial stages, atherosclerosis is characterized by the intimal
recruitment of selected populations of white blood cells, especially
monocytes, and by the gradual accumulation of lipids and extra-
cellular matrix. The endothelium and the underlying collagen lay-
ers overlying the enlarged intima—the so-called fibrous cap—for
a long time during atherosclerosis progression prevent the contact
of the highly thrombogenic lipid core of the plaque with the cir-
culating blood. The sudden rupture of the eventually thin fibrous
cap, from the outside or from the inside (in the latter case due
to the rupture of vasa vasorum penetrating the intima), transforms
this slow process into an acute event, with the sudden develop-
ment of thrombosis [4]. When this occurs in a coronary artery, the
consequent myocardial ischemia, in appropriate conditions, may
precipitate an acute coronary syndrome, that is, acute myocardial
infarction or unstable angina. In the cerebral circulation or in the
cerebro-afferent arteries this may lead to an acute stroke.
The recruitment of monocytes reflects specific molecular
changes in the adhesive properties of the endothelial surface, due
to the surface expression of specific endothelium-leukocyte adhe-
sion molecules (ELAMs) (“athero-ELAMs”). One of the most rel-
evant such proteins is vascular cell adhesion molecule-1 (VCAM-
1). Pathophysiologically, relevant stimuli for VCAM-1 expression
include several causes of increased oxidative stress, such as ox-
idized low density lipoproteins (LDL), many cytokines, the ad-
vanced glycation end-products (AGEs) associated with diabetes,
and possibly also high glucose and high insulin [5]. Once adhered,
monocytes transmigrate, through the action of chemotactic stimuli
also deriving from the activated endothelium, from the blood into
the subendothelial intima, where, upon internalization of modi-
fied lipoproteins, they become macrophages able to secrete proin-
flammatory cytokines. These contribute to maintaining a state of
vascular inflammation, further augmenting the expression of ad-
hesion molecules, chemoattractants, and macrophage-activating
factors, thus initiating a vicious circle leading to lesion progression.
Later on, the production of matrix metalloproteinases
(MMPs)—by the same macrophages as well as by endothelial
cells—may promote the erosion of the collagen layers of the fi-
brous cap and ultimately lead to plaque rupture [6]. The stability of
the atherosclerotic plaque is indeed thought to reflect the balance
and interplay of various dynamic factors, including endothelial
dysfunction, the proliferation of smooth muscle cells (which are
mainly responsible for the synthesis of collagen), and the degra-
dation of collagen and other elements of the extracellular ma-
trix by MMPs, mostly produced by activated macrophages. The
much sought-after prevention of acute vascular events therefore
requires interventions that affect such mechanisms leading on the
one hand to the slow formation of atherosclerotic lesions and on
the other to the sudden precipitation of plaque rupture.
Antiatherogenic Functional Food
and Nutraceuticals
Functional foods and related nutraceuticals claimed as “vasculo-
protective” are a very large, heterogeneous, and ever-increasing
number of substances. A synoptic table reporting the claimed car-
diovascular benefits of a wide array of such bioactive compounds
is provided in Table 2. We will here focus only on the mechanistic
evidence supporting the consumption of two well-known vascu-
loprotective classes of foods, namely:
 fish and fish oil, as a source of ω-3 polyunsaturated fatty acids
(ω-3 FA);
 red wine and olive oil as a source of antioxidant phenols.
ω-3 PUFAs Eicosapentaenoic (EPA) and
Docosahexaenoic (DHA) in Fish and Fish Oil
Since the early studies in Greenland Eskimos, dietary intake of
ω-3 FA, introduced with fish, fish-derived products or supple-
ments, has been consistently associated with cardiovascular pro-
tection [7]. Randomized intervention trials have also by-and-large
shown that ω-3 FA may reduce relevant cardiovascular endpoints,
such as sudden death and fatal myocardial infarction [8,9], with
estimated benefits that exceed the potential vascular risk associ-
ated with methylmercury, dioxins, polychlorinated biphenyls and
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Table 2 Potential cardiovascular benefits of different functional foods and nutraceuticals
Bioactive compound Examples Sources Putative vasculoprotective effects
Flavonols Quercetin, kaempferol, catechin Onion, apple, tea, berries, olives,
broccoli, lettuce, red wine,
cocoa/chocolate
↓TC, ↓LDL-C oxidation↑HDL-C, AOx, ↓platelet
aggregation, ↓eicosanoid synthesis,
↓athero-ELAMs, ↓angiogenesis, ↓MMPs
Flavonols Epicatechin, epigallocatechin,
epicatechin-3-gallate,
epigallocatechin-3-gallate
Green/black tea, cocoa/chocolate AOx, ↓apoptosis, ↓LDL-C oxidation, ↓platelet
aggregation, ↓athero-ELAMs, ↓angiogenesis,
↓MMPs
Lignans Enterolactone, enterodiol Flaxseed oil, lucerne, clover ↓LDL-C, AOx, estrogen/antiestrogen;
↓atherosclerosis in vivo but may show adverse
CVD effect (pro-oxidant activity with partially
defatted flaxseed)
Isoflavones Genistein, daidzein Soybeans, legumes ↓TC and LDL-C, ↓LDL-C oxidation, ↓TG, ↑HDL-C,
↓thrombosis, AOx, estrogen/antiestrogen,
↓athero-ELAMs, ↓angiogenesis,
↓atherosclerosis in vivo, ↓MMPs
Stilbenoids Resveratrol Grapes, red wine, peanuts ↓LDL-C oxidation, ↓platelet
aggregation/thrombosis, ↓eicosanoid
synthesis, AOx, ↓athero-ELAMs, ↓angiogenesis
but promotes angiogenesis in the ischemic
heart, ↓atherosclerosis in vivo, ↓MMPs
Carotenoids Lycopene Tomatoes, tomato products ↓LDL-C and LDL-C oxidation, Aox,
↓athero-ELAMs, ↓MMPs, but no effects was
shown in animal models of ATS and and dietary
intervention studies using well-defined subjects
population did not provided a clear evidence of
lycopene in the prevention of CVD
Carotenoids α-Carotene β-carotene,
γ-carotene, δ-carotene
Carrots, pumpkins, maize,
tangerine, orange and yellow fruits
and vegetables
Inconsistent data. β-carotene have shown
adverse CVD effect because its prooxidant
activity
Organosulfur compounds Allicin, diallyl sulfide, diallyl
disulfide, allyl mercaptan
Garlic, onion, leek ↓TC and LDL-C, ↓TG, ↓cholesterol and FA
synthesis, ↓BP, ↓thrombosis, AOx,
↓athero-ELAMs, ↓angiogenesis,
↓atherosclerosis in vivo, ↓MMPs
Soluble dietary fibers Glucan, pectin, psyllium Oats, barley, yeast, fruit,
vegetables, psyllium seed, fortified
cereals and grains
↓TC, ↓TG, ↓LDL-C
Isothiocyanates Phenethyl (PEITC), benzyl (BITC),
sulforaphanes
Cruciferous vegetables (e.g.,
watercress, broccoli)
no relevant effects
Monoterpenes d-Limonene, perillic acid Essential oils of citrus fruit,
cherries, mint, herbs
↓TC and LDL-C, ↓HMGCoAR, ↓angiogenesis
Plant sterols Sitostanol, stigmasterol,
campesterol
Tall oil, soybean oil, rice bran oil ↓TC and LDL-C, AOx, ↓cholesterol absorption;
adverse effect: ↓carotenoid absorption
Phenolic acids Tyrosol, hydroxytyrosol,
oleoeuropeine, caffeic acid,
cumaric acid
Extra virgin olive oil ↓LDL-C oxidation, ↓platelet
aggregation/thrombosis, ↓eicosanoid
synthesis, AOx, ↓athero-ELAMs,
↓atherosclerosis in vivo, ↓MMPs
ω-3 PUFA DHA, EPA, αLA Fish and fish oil, green leaves ↓TC, suppression of cardiac arrhythmias, ↓BP
↓platelet aggregation, ↓eicosanoid synthesis,
↓athero-ELAMs, ↓angiogenesis; ↓MMPs
Prebiotics Inulin-type fructans Fruit and vegetable, purified
extract from chicory root
↓TC and ↓TG
Probiotics Selected strains of Lactobacillus
acidophilus, Bifidobacterium
bifidum and Lactobacillus
bulgaricus
Fermented milk products ↓TC, LDL-C and BP
AOx, antioxidant activity; BP, blood pressure; CVD, cardiovascular disease; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein
cholesterol; TC, total cholesterol; TG, triglycerides; MMPs, metalloproteinases; ELAMs, endothelial leukocyte adhesion molecules.
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other environmental contaminants that frequently pollute marine
food products [10,11].
The reduced morbidity and mortality from CVD by ω-3 FA
can explained by two main basic mechanisms: the suppression of
cardiac arrhythmias [12]; and reduced athero-thrombotic events,
through the modulation of specific risk factors—reducing platelet
aggregation [13], decreasing plasma triglycerides [14], and blood
pressure [15,16]; and the direct regulation of systemic and lo-
cal inflammation underlying plaque inception, progression, and
instability. The anti-inflammatory and anti-atherogeneic proper-
ties of ω-3 FA have been largely investigated in in vitro, ani-
mal and human studies. Cellular models of early atherogenesis
based on cultured endothelial cells challenged with various pro-
atherogenic stimuli have shown that both DHA and EPA sig-
nificantly inhibit most of the critical events connected with en-
dothelial activation, including the expression of VCAM-1. Such
regulatory effects occur in a range of DHA concentrations compat-
ible with nutritional supplementation to a normal Western diet
and are strictly related in magnitude to the extent of incorpora-
tion into total cell lipids [17–19]. Such “anti-inflammatory” effects
are not limited to the expression of transmembrane molecules
involved in leukocyte recruitment, but also appear to occur for
other cytokine-activated products, such as the pro-inflammatory
and pro-angiogenic enzyme cyclooxygenase (COX)-2 [20], as well
as the pro-inflammatory and chemoattractant soluble proteins
interleukin (IL)-6 [21], IL-8 [18], macrophage-colony stimulat-
ing factor (M-CSF) [22], and monocyte chemoattractant protein
(MCP)-1 [23]. Such effects are accompanied by reduced mono-
cyte adhesion to cytokine-activated endothelium [17,18]. In par-
allel with the modulation of endothelial activation, an antioxi-
dant effect can also be documented in cultured endothelial cells
supplemented with DHA [20,22,24], mostly attributable to the re-
duced membrane assembly and activation of the reactive oxygen
species (ROS)-producing enzyme complex nicotinamide adenine
dinucleotide phosphate (NADPH)-oxidase, likely as a consequence
of the plasma membrane changes occurring upon DHA incorpora-
tion [20] (Figure 1).
Cell treatment with ω-3 FA also favorably influences other cor-
relates of atherosclerotic risk. It was observed that both EPA and
DHA, when supplemented to macrophages in culture, significantly
reduce the stimulated release of MMPs [23,25], thus likely con-
tributing to the plaque-stabilizing effects observed in humans [26].
In addition, fish oils prevent serotonin-induced smooth muscle
cells proliferation [27], an effect that may play a role in preventing
restenosis after an endovascular intervention.
While cellular models of atherosclerosis essentially indicate a
protective role of fish oil, results from animal studies carried out
in nonhuman primates, pigs, rabbits, and mice, although mostly
pointing out to the existence of an anti-aterogenic effect, are
somewhat contradictory, probably due to differences in study
Figure 1 The effects of the ω-3 fatty acid DHA on endothelial VCAM-1 and
COX-2 expression, the generation of reactive oxygen species and the activa-
tion of NAD(P)H oxidase. Immunocytochemical analysis of the effect of DHA
on the stimulated expression of VCAM-1 (A) and COX-2 (B) in endothelial
cells. Human umbilical or saphenous vein endothelial cell (HUVEC or HSVEC)
were treated with 25 μmol/L DHA for 48 h before stimulation with IL-1β
10 ng/mL for 16 h. After incubations, monolayers were immunostained with
anti-VCAM-1andanti-COX-2monoclonal antibodies, respectively. (C)HUVEC
(or HSVEC) were treated as in A. ROS generation was assessed by the oxida-
tion of dichloro-fluoresceine diacetate to a highly fluorescent compound. (D)
Subcellular soluble and particulate (membrane) fractionswere isolated from
HUVEC treated as in A, andWestern blots were performedwith an antibody
specific for the NAD(P)H oxidase subunit p47phox (unpublished data).
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designs and species [23,28,29]. Furthermore, it is not yet clear
whether it is the absolute low amounts of ω-3 FA in the diet or
is the high ratio of ω-6 FA to ω-3 FA—another typical feature of
the pro-atherogenic Western diets—to predispose individuals to
increased CVD disease [30]. In the LDL receptor-null mice, a com-
monly used model of atherosclerosis, results point to a relevance
of the ratio [31].
Finally, complementary studies on angiogenesis have high-
lighted a potential anti-angiogenic activity by ω-3 FA in vitro and
in vivo [32,33], an effect interpreted as promoting plaque stabiliza-
tion [34].
Phenolic Compounds in Red Wine
and Extra-Virgin Olive Oil: Resveratrol
and Hydroxytyrosol as Potential Cardiovascular
Nutraceuticals
By the end of the 1970s findings from epidemiological and clin-
ical studies had indicated that consumption of fruit and vegeta-
bles prevents several major diseases, including cancer and CVD
[35], prompting health authorities to promote consumption of
these foods and clinicians to carry out supplementation trials. The
primary nutrients responsible for providing such protection were
thought to be antioxidant vitamins, which are abundant in fruit
and vegetables [36]. However, when the role of individual an-
tioxidants, such as vitamins C, E, and carotenoids, was examined
in controlled trials, the results were clearly disappointing [37].
It was therefore proposed that only the whole fruit and vegeta-
bles, containing a very vast array of antioxidant components in
optimally balanced amounts, may provide the optimal “polyphar-
macy” against the development of atherosclerosis.
Mediterranean diets, known for being associated with cardio-
vascular protection [38], are characterized by a low consumption
of butter and red meat, a high intake of antioxidant phenol-rich
vegetables and fruits, but also the olive-related derivative olive oil,
as well as red wine. Hydroxytyrosol and resveratrol are the two
major antioxidant phenols contained in olive oil and red wine, re-
spectively. Several human studies have pointed out to a vasculo-
protective effect for both resveratrol and hydroxytyrosol [39,40],
and many efforts have been made to characterize their biologi-
cal mechanisms of action. Although studies in animal models of
atherosclerosis overall agree on an anti-atherogenic effect of both
red wine and resveratrol [41–43], the use of olive oil and hy-
droxytyrosol has produced conflicting results, with olive oil usu-
ally reducing [44–46], while hydroxytyrosol sometimes promot-
ing the development of atherosclerotic lesions [47]. These data
support the concept that phenolic components-enriched prod-
ucts, out of the original matrix, might not only be useless but
also harmful, and suggest that the formulation of functional foods
should approximate—as much as possible—the natural environ-
ment in which active molecules are found. Results obtained in
cellular models of atherosclerosis conversely confirm the protec-
tive role for both hydroxytyrosol and resveratrol furnishing plau-
sible mechanistic explanations for the protective effects observed
in humans. Both resveratrol and hydroxytyrosol inhibit lipid per-
oxidation, while resveratrol also enhances the cholesterol efflux
by upregulating the ATP-binding cassette, sub-family A [ABCA]-
0
5
10
15
Oleic Acid, 50 μmol/L, 48 h
Control
HT, 50 μmol/L, 30 min
PMA 10 nmol/L+ + ++−
**
Pro-MMP-9
antigen
release
(ng/mL)
Oleic Acid + HT 
**
20
Figure 2 Hydoxytyrosol inhibits the PMA-induced expression of MMP-9 in
U937cells. Fiftyμmol/Lhydroxytyrosol or50μmol/Loleic acid (orboth)were
added to monocytoid U937 cells for the indicated time before adding phor-
bol myristate acetate (PMA) for further 24 h, after which matrix metallopro-
teinase (MMP)-9 released in themediumwas determined by a soluble-phase
EIA (∗∗P < 0.001) (unpublished data).
1 receptors [48,49]. Both compounds inhibit platelet aggregation
[50,51] and the synthesis of eicosanoids, but only resveratrol sup-
presses the induction of tissue factor (TF) in endothelial cells and
monocytes [52]. Finally, hydroxytyrosol and resveratrol reduce
the expression of VCAM-1 in endothelial cells stimulated by vari-
ous proinflammatory and proatherogenic stimuli [53,54], an effect
largely mediated by the reduced activation of the redox-sensitive
transcription factor nuclear factor(NF)-κB [53]. Furthermore, re-
cent findings from our laboratory indicate that hydroxytyrosol
may improve plaque stability by reducing the stimulated release of
MMP-9 by macrophages in culture (Figure 2). Interestingly, such
effect was even more evident in the presence of oleic acid, a typi-
cal macro-component of olive oil, in agreement with the concept
that functional foods may exert a better protective effect when the
natural food matrix is maintained. It must however be remarked
that clinical trials with selected Mediterranean diet antioxidants
are missing, and that these compounds are therefore mostly seen
as acting in concert with the nutritional matrix and other compo-
nents.
Conclusions and Perspectives
More than for any other disease, CVD appear to be highly sensi-
tive to nutritional intervention. However, while for decades nu-
tritional recommendations have focused on negative messages –
what not to eat –, today the other side of the nutritional coin—what
to eat—is equally, if not more, importantly emphasized. Impressive
progress has been made over the past three decades in defining
the role of bioactive compounds in reducing the risk of atheroscle-
rotic vascular disease, also unraveling some of the underlying bi-
ological mechanisms. Here we have summarized some of the ev-
idence linking ω-3 FA and selected antioxidant polyphenols with
protection from atherosclerosis. For them, the concerted tran-
scriptional control of several pro-inflammatory genes implicated
in atherosclerosis likely plays a key role. Such quantitatively mi-
nor bioactive dietary components appear overall to fine-tune the
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response of our genes to dangerous environmental challenges,
curbing physiological responses without abrogating them to-
tally. By decreasing the endothelial responsiveness to pro-
inflammatory, pro-atherogenic, and pro-angiogenic stimuli, they
appear to impact molecular events not targeted by any other drugs
or interventions. Their potential preventive or therapeutic role ap-
pears therefore complementary to those of already enacted phar-
macological treatments. Overall, one has, however, to remark that
clinical evidence for the health benefits of these compounds is
much stronger for ω-3 FA than for antioxidant polyphenols of the
Mediterranean diet. Clearly, more clinical research is necessary,
especially with these latter compounds.
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